leukemia
![venclexta multiple myeloma trial, venclexta trial results, venclexta label expansion, abbvie roche venclexta, venclexta progression free survival, venclexta blood cancer, venclexta failed endpoint,](https://pharmtales.com/wp-content/uploads/2023/09/Venclexta-fails-to-meet-primary-endpoint-in-multiple-myeloma-trial.jpg)
Venclexta fails to meet primary endpoint in multiple myeloma trial
Anika Sharma
AbbVie and Roche, pioneers in the field of leukemia treatments with Venclexta, faced a setback as their hopes to expand ...
![CAR T-cell therapy, blood cancer treatment, immunotherapy, personalized targeting, breakthrough, benefits, risks, approved therapies, leukemia, lymphoma, multiple myeloma,](https://pharmtales.com/wp-content/uploads/2023/08/CAR-T-Cell-Therapy-in-Hematological-Malignancies.jpg)
CAR T-Cell Therapy in Hematological Malignancies: A Breakthrough or a Bust?
Anika Sharma
Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nodes. They include leukemia, lymphoma, and multiple myeloma. ...